Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test a new drug for neuroendocrine tumors. We think that this
new drug may help control your tumor.
MK-0646 is a monoclonal antibody. An antibody is a protein that is able to attach to specific
target on cancer cells. This target helps the cancer cells grow and divide. By attaching to
the target, it may stop the cancer cells from further growth and dividing. This study will
help find out if MK-0646 is a helpful drug when taken in patients with neuroendocrine tumor.
This study is a phase 2 study. The purpose of a phase 2 study is to find out what effects,
good and/or bad, MK-0646 has on metastatic neuroendocrine tumors.